Dale Miles

2.2k total citations
70 papers, 1.6k citations indexed

About

Dale Miles is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dale Miles has authored 70 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 26 papers in Molecular Biology and 24 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dale Miles's work include Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (12 papers) and CAR-T cell therapy research (9 papers). Dale Miles is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (12 papers) and CAR-T cell therapy research (9 papers). Dale Miles collaborates with scholars based in United States, France and Australia. Dale Miles's co-authors include Linh T. Nguyen, Steven Lacy, Richard A. Miller, Patricia LoRusso, Kathryn W. Woodburn, Darren Magda, Chunze Li, Geoffrey I. Shapiro, Stuart W. Young and Harold Keer and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Blood.

In The Last Decade

Dale Miles

70 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dale Miles United States	23	663	635	575	223	171	70	1.6k
Gerald J. Fetterly United States	24	901 1.4×	609 1.0×	378 0.7×	81 0.4×	98 0.6×	88	1.9k
Muhammad Wasif Saif United States	25	562 0.8×	1.7k 2.7×	639 1.1×	122 0.5×	91 0.5×	129	2.7k
M. Boisdron‐Celle France	27	803 1.2×	2.1k 3.2×	589 1.0×	205 0.9×	91 0.5×	65	3.1k
Daniel Wahl United States	23	780 1.2×	503 0.8×	308 0.5×	250 1.1×	204 1.2×	79	2.2k
Christine M. Walko United States	24	473 0.7×	992 1.6×	454 0.8×	112 0.5×	94 0.5×	84	2.0k
Richard J. Honeywell Netherlands	26	1.0k 1.6×	822 1.3×	477 0.8×	163 0.7×	61 0.4×	77	1.9k
Remy B. Verheijen Netherlands	18	542 0.8×	630 1.0×	794 1.4×	180 0.8×	86 0.5×	50	1.4k
Anne M. Traynor United States	32	933 1.4×	1.3k 2.1×	1.1k 2.0×	158 0.7×	261 1.5×	117	2.9k
Stijn L.W. Koolen Netherlands	25	545 0.8×	1.1k 1.7×	755 1.3×	231 1.0×	188 1.1×	155	2.3k
Yusuke Demizu Japan	28	795 1.2×	687 1.1×	1.3k 2.2×	127 0.6×	245 1.4×	106	3.0k

Countries citing papers authored by Dale Miles

Since Specialization

Citations

This map shows the geographic impact of Dale Miles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dale Miles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dale Miles more than expected).

Fields of papers citing papers by Dale Miles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dale Miles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dale Miles. The network helps show where Dale Miles may publish in the future.

Co-authorship network of co-authors of Dale Miles

This figure shows the co-authorship network connecting the top 25 collaborators of Dale Miles. A scholar is included among the top collaborators of Dale Miles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dale Miles. Dale Miles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mody, Hardik, Dhruvitkumar S. Sutaria, & Dale Miles. (2024). Clinical Pharmacology Considerations for the “Off‐the‐Shelf” Allogeneic Cell Therapies. Clinical Pharmacology & Therapeutics. 115(6). 1233–1250. 3 indexed citations

Shriver, Sharon P., Jeannine S. McCune, Dale Miles, et al.. (2024). Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology. Journal of Clinical Oncology. 42(10). 1181–1192. 9 indexed citations

Joslyn, Louis R., Weize Huang, Dale Miles, Iraj Hosseini, & Saroja Ramanujan. (2024). Digital twins elucidate critical role of Tscm in clinical persistence of TCR-engineered cell therapy. npj Systems Biology and Applications. 10(1). 11–11. 11 indexed citations

Liao, Michael Z., Rong Deng, Leonid Gibiansky, et al.. (2023). Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non‐Asian patients with previously untreated diffuse large B‐cell lymphoma in POLARIX. Clinical and Translational Science. 16(12). 2744–2755. 3 indexed citations

Samineni, Divya, Leonid Gibiansky, Bei Wang, et al.. (2022). Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial. Advances in Therapy. 39(8). 3635–3653. 7 indexed citations

Shemesh, Colby S., Priya Agarwal, Tong Lu, et al.. (2020). Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. Cancer Chemotherapy and Pharmacology. 85(5). 831–842. 11 indexed citations

Lü, Dan, Tong Lu, Leonid Gibiansky, et al.. (2020). Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma. Pharmaceutical Research. 37(12). 252–252. 13 indexed citations

Lacy, Steven, et al.. (2018). A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types. Cancer Chemotherapy and Pharmacology. 81(6). 1071–1082. 28 indexed citations

Wakelee, Heather A., Scott Gettinger, Jeffrey A. Engelman, et al.. (2017). A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 79(5). 923–932. 29 indexed citations

10.

Miles, Dale, et al.. (2016). Population pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in medullary thyroid cancer patients receiving cabozantinib. Anti-Cancer Drugs. 27(4). 328–341. 12 indexed citations

11.

Nguyen, Linh T., et al.. (2015). Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. The Journal of Clinical Pharmacology. 55(9). 1012–1023. 66 indexed citations

12.

Miles, Dale, Nelson L. ‘Shasha’ Jumbe, Steven Lacy, & Linh T. Nguyen. (2015). Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis. Clinical Pharmacokinetics. 55(1). 93–105. 30 indexed citations

13.

Papadopoulos, Kyriakos P., Josep Tabernero, Ben Markman, et al.. (2014). Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(9). 2445–2456. 87 indexed citations

14.

Shapiro, Geoffrey I., E. Heath, Lisa Malburg, et al.. (2007). A Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor, administered daily to patients (pts) with advanced malignancies. Molecular Cancer Therapeutics. 6. 8 indexed citations

15.

Magda, Darren, Philip Lecane, Richard A. Miller, et al.. (2005). Motexafin Gadolinium Disrupts Zinc Metabolism in Human Cancer Cell Lines. Cancer Research. 65(9). 3837–3845. 53 indexed citations

16.

Mani, Chitra, et al.. (2005). Reductase‐mediated metabolism of motexafin gadolinium (Xcytrin®) in rat and human liver subcellular fractions and purified enzyme preparations. Journal of Pharmaceutical Sciences. 94(3). 559–570. 6 indexed citations

17.

Magda, Darren, et al.. (2005). Gadolinium texaphyrin–methotrexate conjugates. Towards improved cancer chemotherapeutic agents. Organic & Biomolecular Chemistry. 3(18). 3290–3290. 21 indexed citations

18.

Miles, Dale, Jennifer A. Smith, See‐Chun Phan, et al.. (2005). Population Pharmacokinetics of Motexafin Gadolinium in Adults With Brain Metastases or Glioblastoma Multiforme. The Journal of Clinical Pharmacology. 45(3). 299–312. 10 indexed citations

19.

Miles, Dale, et al.. (2003). Quantitation of motexafin lutetium in human plasma by liquid chromatography-tandem mass spectrometry and inductively coupled plasma-atomic emission spectroscopy. PubMed. 5(3). 1–16. 18 indexed citations

20.

Woodburn, Kathryn W., Quli Fan, Dale Miles, et al.. (1997). Localization and Efficacy Analysis of the Phototherapeutic Lutetium Texaphyrin (PCI‐0123) in the Murine EMT6 Sarcoma Model. Photochemistry and Photobiology. 65(3). 410–415. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact